CORDIS · 101104574 · HORIZON
DE-ESCALATE INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN THE ERA OF ANDROGEN RECEPTOR PATHWAY INHIBITORS; A PHASE 3 PRAGMATIC RANDOMISED TRIAL
Coordinator: EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL (BE)
Prostate Cancer is the most common cancer in European men. Despite dramatic improvements in early diagnostic and local treatment, one out of five prostate cancer patients will die from their disease. Despite progress in the past years, it remains critical to improve on the present strategy for advanced and metastatic prostate cancer. Within the proposed project, we will evaluate whether intermittent intensified androgen deprivation treatment (iADT) in metastatic prostate cancer is not inferior to continuous treatment in terms of oncological benefit while minimizing side effects and resource u…
About Horizon Europe (2021–2027)
Horizon Europe is the EU's current research and innovation programme, covering 2021 to 2027 with a budget of roughly €95.5 billion. Its three pillars are Excellent Science (frontier research and mobility), Global Challenges and European Industrial Competitiveness (mission-driven collaborative projects in health, climate, digital, security and food) and Innovative Europe (the EIC and EIT). It also funds five EU Missions targeting cancer, climate adaptation, smart cities, oceans and soils.
EU contribution: €7.2M awarded to the consortium. The project runs over approximately 5 years from 2023-06-01 to 2028-05-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from BE
see all →- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · H2020 · €178.2M
- SGA1-HE — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101052416 · HORIZON · €153.0M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · H2020 · €150.0M
- SGA2 — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101197135 · HORIZON · €120.0M
- SGA3 — COST - Maximising impact861952 · H2020 · €81.8M
- EIT Digital BP — EIT Digital Sustainable Growth101113245 · HORIZON · €33.7M
Other HORIZON projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon Europe through a joint programme of the members of the EUROfusion consortium101052200 · DE · €549.4M
- EITUM-BP26-28 — EIT Urban Mobility Business Plan 2026-2028101269525 · ES · €206.9M
- PARC — Partnership for the Assessment of Risks from Chemicals101057014 · FR · €200.0M
- EIT RM BP23-25 — EIT RawMatrials Business Plan 2023-2025101113034 · DE · €155.5M
- EIT HEI — EIT Higher Education Initiative - Scaling Europe’s Innovation Ecosystems101270329 · DE · €130.0M
- Biodiversa-plus — The European Biodiversity Partnership101052342 · FR · €105.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon Europe (2021–2027) programme, under the HORIZON-RIA funding scheme.
- What is the EU contribution?
- The European Commission contributes €7.2M.
- Which EU programme funds it?
- The project is funded under Horizon Europe (2021–2027), call HORIZON-MISS-2022-CANCER-01.
- Who coordinates the project?
- The project is coordinated by EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL (BE).
- What is the project timeline?
- The project runs from 2023-06-01 to 2028-05-31 — approximately 5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 101104574.